Goldman Sachs
TVGN icon

Goldman Sachs’s Tevogen Bio Holdings TVGN Stock Holding History

Goldman Sachs’s Portfolio TVGN Stock Details TVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,474
Closed -$90.6K – 7067
2025
Q4 		$90.6K Buy
5,474
+3,052
+126% +$79.3K ﹤0.01% 6206
2025
Q3 		$95.1K Buy
2,422
+820
+51% +$40.3K ﹤0.01% 6088
2025
Q2 		$100K Buy
1,602
+507
+46% +$28.9K ﹤0.01% 5817
2025
Q1 		$59.1K Sell
1,095
-468
-30% -$30.8K ﹤0.01% 5867
2024
Q4 		$80.5K Buy
1,563
+831
+114% +$54.1K ﹤0.01% 5799
2024
Q3 		$13.5K Buy
+732
New +$21.4K ﹤0.01% 5691
2022
Q3 		– Sell
-4,327
Closed -$2.17M – 6570
2022
Q2 		$2.17M Hold
4,327
– – ﹤0.01% 3978
2022
Q1 		$2.16M Buy
+4,327
New +$2.15M ﹤0.01% 4193

Other funds holding TVGN

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Goldman Sachs's TVGN Position: Q1 2026 in Review

Goldman Sachs sold out of Tevogen Bio Holdings (TVGN) in Q1 2026, closing a stake of 5,474 shares — an estimated $90.6K sold.

Goldman Sachs first reported a position in TVGN in Q1 2022 and held it in 8 quarters. The position peaked at $2.17M in Q2 2022. 30 funds tracked by Wall St. Rank hold TVGN as of Q1 2026.

  • Goldman Sachs reported no remaining Tevogen Bio Holdings position as of Q1 2026 after selling out during the quarter.
  • Goldman Sachs sold 5,474 Tevogen Bio Holdings shares in Q1 2026, an estimated $90.6K.
  • Goldman Sachs first reported a position in Tevogen Bio Holdings in Q1 2022 and held it in 8 quarters.
  • Goldman Sachs's Tevogen Bio Holdings position peaked at $2.17M in Q2 2022.
  • 30 funds tracked by Wall St. Rank held Tevogen Bio Holdings as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.